Restricted accessOtherFirst published online 2005-4
Vesiculo-erosive Oral Mucosal Disease—Management with Topical Corticosteroids: (2) Protocols,Monitoring of Effects and Adverse Reactions,and the Future
Although topical corticosteroids (TCs) are the most widely used drugs in oral medicine, and specifically in the treatment of vesiculo-erosive oral mucosal disease, there are few evidence-based data for the correct use of these drugs. In this review, we outline the most widely used protocols, the most common reasons for treatment failure, and the adverse effects documented in the literature.
Get full access to this article
View all access options for this article.
References
1.
Addy M -1980-. The oral mucosa absorption and tissue distribution of triamcinolone acetonide in the dog studied by autoradiography. Arch Oral Biol25:809–817.
2.
Adinoff AD, Hollister JR -1983-. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med309:265–268.
3.
Allenby CF, Main RA, Marsden RA, Sparkes CG -1975-. Effect on adrenal function of topically applied clobetasol propionate -Dermobate-. Br Med J4:619–621.
4.
Bircher AJ, Pelloni F, Langauer S, Müller D -1996-. Delayed hypersensitivity reactions to corticosteroids applied to mucous membranes. Br J Dermatol135:310–313.
5.
Carbone M, Conrott D, Carrozzo M, Broccoletti R, Gandolfo S, Scully C -1999-. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide. Oral Diseases5:44–49.
6.
Carr RD, Wieland RG -1996-. Corticosteroid reservoir in the stratum corneum. Arch Dermatol94:81–84.
7.
Carruthers JA, August PJ, Staughton RCD -1975-. Observations on the systemic effect of topical clobetasol propionate ointment. Br Med J4:203–204.
8.
Chan LS, Razzaque Ahmed A, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. -2002-. The first international consensus on mucous membrane pemphigoid. Arch Dermatol138:370–379.
9.
Editorial -1975-. Steroid therapy of the adrenals. Lancet2:537.
10.
Feldman RJ, Maibach HI -1965-. Penetration of C14 hydrocortisone through normal skin: the effect of stripping and occlusion. Arch Dermatol91:661–666.
11.
Frey BM, Frey FJ, Holford NH, Lozada F, Benet LZ -1982-. Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. Transplantation33:578–584.
12.
Frey FJ, Amend WJC, Lozada F, Frey BM, Benet LZ -1981-. Endogenous hydrocortisone, a possible factor contributing to the genesis of Cushingoid habitus in patients on prednisone. J Clin Endrocinol Metab5:1076–1080.
13.
Gill KA, Baxter DL -1964-. Plasma cortisol suppression by steroid creams. Arch Dermatol89:734–740.
14.
Gilman AG, Goodman LS, Rall TW, Murad R, editors -1985-. The pharmacological basis of therapeutics. New York: Macmillan Publishing Company, pp. 1459–1489.
González-Moles MA, González-Moles S, Ruiz Ávila I, Esteban F, Galindo Moreno P, Rodríguez Archilla A -1996-. Epithelial response to the immunitary aggression in oral lichen planus. Acta Stomatol Belg3:119–123.
17.
González-Moles MA, Morales-García P, Rodríguez-Archilla A -2002a-. Clobetasol mouthwash is effective for severe oral erosive lesions. Dent Abstr47:268.
18.
González-Moles MA, Morales-García P, Rodríguez-Archilla A, Ruiz-Ávila I, González-Moles S -2002b-. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod93:264–270.
19.
González-Moles MA, Morales-García P, Rodríguez-Archilla A, Ruiz-Ávila I, Mesa-Aguado F, Bascones-Martínez A, et al. -2003-. Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays. Oral Surg Oral Med Oral Pathol Oral Radiol Endod95:688–692.
20.
Holmstrup P, Schiotz AW, Westergaard J -1990-. Effect of dental plaque control on gingival lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod69:585–590.
21.
Holroyd SV, Wynn RL -1983-. Clinical pharmacology in dental practice. St. Louis: C.V. Mosby.
22.
Kirketerp M -1964-. Systemic effects of local treatment with fluocinolone acetonide applied under a plastic film. Acta Dermato-Venereol44:54–58.
23.
Lehner T, Lyne C -1969-. Adrenal function during topical oral corticosteroid treatment. Br Dent J4:138–141.
24.
Lehner T, Lyne C -1970-. Adrenal function during topical oral treatment with triamcinolone acetonide. Br Dent J129:164–167.
25.
Livanou T, Ferriman D, James VHT -1967-. Recovery of hipothalamo-pituitary-adrenal function after corticosteroid therapy. Lancet2:856–859.
26.
Lo Muzio L, Della Valle A, Mignogna MD, Pannone G, Bucci P, Bucci E -2001-. The treatment of oral aphthous ulceration or erosive lichen planus with topical clobetasol propionate in three preparations: a clinical and pilot study on 54 patients. J Oral Pathol Med30:611–617.
27.
Lozada F -1980-. Topically applied fluocinonide in an adhesive base in the treatment of oral vesiculoerosive diseases. Arch Dermatol116:898–901.
28.
Lozada F, Frey F, Benet L -1983-. Prednisolone clearance: a possible determinant for glucocorticoid efficacy in patients with oral vesiculoerosive diseases. J Dent Res62:575–577.
29.
Lozada-Nur F, Miranda C -1997-. Oral lichen planus: topical and systemic therapy. Sem Cutan Med Surg16:295–300.
30.
Lozada-Nur F, Silverman S -1980-. Topically applied fluocinonide in adhesive base in the treatment of oral vesiculo-erosive diseases. Arch Dermatol116:898–901.
31.
Lozada-Nur F, Huang MZ, Zhou G -1991-. Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod71:283–287.
32.
Lozada-Nur F, Miranda C, Maliksi R -1994a-. Double-blind clinical trial of 0.05% clobetasol propionate ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod77:598–604.
33.
Lozada-Nur F, Robinson J, Regezi JA -1994b-. Oral hairy leukoplakia in nonimmunosuppressed patients: report of four cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod78:599–602.
34.
Malkinson FD -1958-. Studies on the percutaneous absorption of C14 labelled steroids by the use of a gas flow cell. J Invest Dermatol31:19–28.
35.
McGrath C, Hegarty AM, Hodgson TA, Porter SR -2003-. Patient-centred outcome measures for oral mucosal disease are sensitive to treatment. Int J Oral Maxillofac Surg32:334–336.
36.
Pimlott SJ, Walker DM -1983-. A controlled clinical trial of efficacy of topically applied fluocinonide in the treatment of recurrent aphthous ulceration. Br Dent J154:174–177.
37.
Plemons JM, Rees TD, Zachariah NY -1990-. Absorption of a topical steroid and evaluation of adrenal suppression in patients with erosive lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod69:688–693.
38.
Robinson JC, Lozada-Nur F, Frieden I -1997-. Oral pemphigus vulgaris: a review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod84:349–355.
39.
Ronbeck BA, Lind PO, Thrane S -1990-. Desquamative gingivitis: preliminary observations with tetracycline treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod69:694–697.
40.
Schaefer H, Zesch S, Stuttgen G -1977-. Penetration, permeation, and absorption of triamcinolone acetonide in normal and psoriatic skin. Arch Dermatol Res258:241–249.
41.
Scheuplein RJ, Blank IH, Brauner GJ, MacFarlane DJ -1969-. Percutaneous absorption of steroids. J Invest Dermatol52:63–70.
42.
Schlaghecke R, Kornely E, Santen RT, Ridderskamp P -1992-. The effect of longterm glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med326:226.
43.
Scoggins RB -1962-. Decrease of urinary corticosteroids following application of fluocinolone acetonide under an occlusive dressing. J Invest Dermatol42:473–474.
44.
Scully C, Carrozzo M, Gandolfo S, Puiatti P, Monteil R -1999-. Update on mucous membrane pemphigoid: a heterogeneous immune-mediated subepithelial blistering entity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod88:56–68.
45.
Selye H -1950-. Stress and the general adaptation syndrome. Br Med J4667:1383–1392.
46.
Silverman S, Lozada-Nur F, Migliorati C -1985-. Clinical efficacy of prednisone in the treatment of patients with oral inflammatory ulcerative diseases: a study of fifty-five patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod59:360–363.
47.
Silverman S Jr, Gorsky M, Lozada-Nur F, Giannotti K -1991-. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod72:665–670.
48.
Squier CA, Johnson NW -1975-. Permeability of oral mucosa. Br Med Bull31:169–175.
49.
Thongprasom K, Luang Jarmekorn L, Seretat T, Taweesap W -1992-. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in the treatment of oral lichen planus. J Oral Pathol Med21:456–458.
50.
Vincent SD, Baker KA, Williams TP -1990-. Oral lichen planus: the clinical, historical, and therapeutic features of 100 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod70:165–171.
51.
Walsh P, Aeling JL, Huff L, Weston WL -1993-. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol29:501–503.
52.
Westerhof W -1989-. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol20:458–461.
53.
Williamson LW, Lorson EL, Sobón DB -1980-. Hypothalamic-pituitary-adrenal-suppression after short-term dexamethasone therapy for oral procedures. J Oral Surg38:20–28.
